Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARGARET VON MEHREN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1144243858
CMS profile
233516
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,481.32

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,480.00 2
Food and Beverage $1.32 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $1,980.00 1
PFIZER INC. $1,501.32 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARGARET VON MEHREN

NPI 1144243858 · CMS profile ID 233516

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $3,481.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $1,980.0005/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686543021 CMS
PFIZER INC. $1,500.0001/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673757429 CMS
PFIZER INC. $1.3201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673262617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,481.32 3
PY2022 $16,889.37 14
PY2024 $17,850.01 21
PY2025 $107.49 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $439.96 2
PY2025 Principal investigator $3,999,133.04 151
PY2024 Principal investigator $2,114,235.16 59
PY2023 Principal investigator $1,626,861.83 207
PY2022 Recipient $12,046.00 1
PY2022 Principal investigator $1,964,612.75 261
PY2021 Principal investigator $4,056,403.36 219
PY2020 Recipient $1,210.00 1
PY2020 Principal investigator $2,320,213.22 69
PY2019 Principal investigator $1,242,313.06 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

70 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Blueprint Medicines Corporation $11,639.88 12/24/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727733
Principal investigator 1 Blueprint Medicines Corporation $24,314.06 12/24/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727737
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,300.00 12/24/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133711
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,754.00 12/24/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133713
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,754.00 12/24/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133717
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,300.00 12/24/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133719
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,122.00 12/24/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133721
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 12/24/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133723
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,560.00 12/24/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133725
Principal investigator 1 Deciphera Pharmaceuticals Inc. $311.78 12/17/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 737133349
Principal investigator 1 Deciphera Pharmaceuticals Inc. $311.78 12/17/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 737133351
Principal investigator 1 Blueprint Medicines Corporation $3,000.00 12/15/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
BLU-285-1101 No dispute reported 06/30/2026 750729273
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,361.00 12/09/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133011
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,271.00 12/09/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133017
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,460.00 12/09/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133021
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,754.00 12/09/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133031
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,653.00 12/09/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737133033
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 12/08/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 737131295
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 12/08/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 737131297
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 12/08/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 737131299
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,814.35 12/08/2020 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 737131301
Principal investigator 1 Deciphera Pharmaceuticals Inc. $160,000.00 11/18/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 737132187
Principal investigator 1 Deciphera Pharmaceuticals Inc. $576,000.00 11/18/2020 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 737132189
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,850.00 11/18/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 964316995
Principal investigator 1 Blueprint Medicines Corporation $7,885.00 11/16/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
BLU-285-1101 No dispute reported 06/30/2026 750729271
Principal investigator 1 Blueprint Medicines Corporation $4,389.84 11/05/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727741
Principal investigator 1 Blueprint Medicines Corporation $4,336.78 10/15/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727739
Principal investigator 1 Blueprint Medicines Corporation $20,898.93 09/17/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727681
Principal investigator 1 Blueprint Medicines Corporation $28,959.13 09/17/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727685
Principal investigator 1 Blueprint Medicines Corporation $34,240.01 09/17/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727689
Principal investigator 1 Blueprint Medicines Corporation $50,823.94 09/17/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727691
Principal investigator 1 Blueprint Medicines Corporation $719.98 09/17/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727701
Principal investigator 1 Blueprint Medicines Corporation $4,336.78 08/20/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727697
Principal investigator 1 Blueprint Medicines Corporation $3,375.60 07/23/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727695
Principal investigator 1 Blueprint Medicines Corporation $27,346.38 06/25/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727645
Principal investigator 1 Blueprint Medicines Corporation $8,673.56 06/18/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727655
Principal investigator 1 Blueprint Medicines Corporation $10.09 05/28/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727641
Principal investigator 1 Blueprint Medicines Corporation $250.00 05/28/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727647
Principal investigator 1 Blueprint Medicines Corporation $8,130.86 05/28/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727651
Principal investigator 1 Blueprint Medicines Corporation $9,829.00 04/30/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
BLU-285-1101 No dispute reported 06/30/2026 750729267
Principal investigator 1 Blueprint Medicines Corporation $193,602.00 04/28/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
BLU-285-1101 No dispute reported 06/30/2026 750729265
Principal investigator 1 Blueprint Medicines Corporation $16,907.13 04/16/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727633
Principal investigator 1 Blueprint Medicines Corporation $146.66 04/16/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727637
Principal investigator 1 Blueprint Medicines Corporation $22,105.06 04/16/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 750727639
Principal investigator 1 Blueprint Medicines Corporation $304.00 04/16/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
BLU-285-1101 No dispute reported 06/30/2026 750729261
Principal investigator 1 Blueprint Medicines Corporation $8,384.00 04/14/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
BLU-285-1101 No dispute reported 06/30/2026 750729255
Principal investigator 1 Blueprint Medicines Corporation $4,192.00 04/14/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
BLU-285-1101 No dispute reported 06/30/2026 750729259
Principal investigator 1 Blueprint Medicines Corporation $4,192.00 04/14/2020 Covered Recipient Teaching Hospital
American Oncologic Hospial
BLU-285-1101 No dispute reported 06/30/2026 750729277
Principal investigator 1 Blueprint Medicines Corporation $19,020.00 03/12/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727523
Principal investigator 1 Blueprint Medicines Corporation $961.18 03/12/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727535
Principal investigator 1 Merck Sharp & Dohme Corporation $9,580.40 03/09/2020 Non-covered Recipient Entity
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
The Targeted Agent and Profiling Utilization Registry TAPUR Study No dispute reported 06/30/2026 740848681
Principal investigator 1 Blueprint Medicines Corporation $63,356.93 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727209
Principal investigator 1 Blueprint Medicines Corporation $174.74 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727495
Principal investigator 1 Blueprint Medicines Corporation $19,061.25 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727499
Principal investigator 1 Blueprint Medicines Corporation $129.20 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727501
Principal investigator 1 Blueprint Medicines Corporation $23,520.50 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727507
Principal investigator 1 Blueprint Medicines Corporation $1,142.60 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727511
Principal investigator 1 Blueprint Medicines Corporation $983.32 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727515
Principal investigator 1 Blueprint Medicines Corporation $3,538.43 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727517
Principal investigator 1 Blueprint Medicines Corporation $85.60 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727521
Principal investigator 1 Blueprint Medicines Corporation $74.78 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727527
Principal investigator 1 Blueprint Medicines Corporation $1,687.80 02/27/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727533
Principal investigator 1 Blueprint Medicines Corporation $20,861.26 02/20/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727529
Principal investigator 1 Novartis Pharmaceuticals Corporation $354,384.80 02/20/2020 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
AN OPEN LABEL MULTI CENTER IMATINIB ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED IMATINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED IMATINIB TREATMENT No dispute reported 06/30/2026 721491233
Principal investigator 1 Merck Sharp & Dohme Corporation $9,580.40 02/10/2020 Non-covered Recipient Entity
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
The Targeted Agent and Profiling Utilization Registry TAPUR Study No dispute reported 06/30/2026 740846983
Principal investigator 1 Novartis Pharmaceuticals Corporation $480,519.04 01/30/2020 Non-covered Recipient Entity
DANA FARBER CANCER INSTITUTE
PHASE II TRIAL OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS IN ADVANCED DEDIFFERENTIATED LIPOSARCOMA DDL AND LEIOMYOSARCOMA LMS No dispute reported 06/30/2026 721491007
Principal investigator 1 Merck Sharp & Dohme Corporation $9,580.40 01/16/2020 Non-covered Recipient Entity
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
The Targeted Agent and Profiling Utilization Registry TAPUR Study No dispute reported 06/30/2026 740846233
Principal investigator 1 Blueprint Medicines Corporation $2,792.56 01/09/2020 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 750727505
Recipient Eli Lilly and Company $1,210.00 01/07/2020 Covered Recipient Physician A PHASE 1B OPEN-LABEL - PHASE 2 RANDOMIZED, DOUBLE-BLINDED STUDY EVALUATING GEMCITABINE AND DOCETAXEL WITH OR WITHOUT OLARATUMAB IN THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA No dispute reported 06/30/2026 728722981
Principal investigator 1 Merck Sharp & Dohme Corporation $9,580.40 01/02/2020 Non-covered Recipient Entity
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
The Targeted Agent and Profiling Utilization Registry TAPUR Study No dispute reported 06/30/2026 740846241